Reduction in adverse transfusion reactions with increased use of washed platelet concentrates in Japan—A retrospective multicenter study
Plasma removal by washing platelet concentrates (PCs) is effective in preventing adverse reactions to PC transfusions. The Japanese Red Cross Society (JRCS) started releasing washed PCs (WPCs) as a commercially approved blood product in September 2016. This retrospective multicenter study investigat...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Ikebe, Emi [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2019transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
7 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease - Lopategi, A. ELSEVIER, 2016, official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, Oxford |
|---|---|
| Übergeordnetes Werk: |
volume:58 ; year:2019 ; number:2 ; pages:162-168 ; extent:7 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.transci.2018.12.021 |
|---|
| Katalog-ID: |
ELV046545433 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV046545433 | ||
| 003 | DE-627 | ||
| 005 | 20230626013912.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191021s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.transci.2018.12.021 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000598.pica |
| 035 | |a (DE-627)ELV046545433 | ||
| 035 | |a (ELSEVIER)S1473-0502(18)30416-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.44 |2 bkl | ||
| 100 | 1 | |a Ikebe, Emi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Reduction in adverse transfusion reactions with increased use of washed platelet concentrates in Japan—A retrospective multicenter study |
| 264 | 1 | |c 2019transfer abstract | |
| 300 | |a 7 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Plasma removal by washing platelet concentrates (PCs) is effective in preventing adverse reactions to PC transfusions. The Japanese Red Cross Society (JRCS) started releasing washed PCs (WPCs) as a commercially approved blood product in September 2016. This retrospective multicenter study investigated the change in the number of transfused WPCs and the impact on the incidence of adverse reactions to PCs before and after the release. The numbers and types of transfused PCs and the adverse reactions to the PCs for a year before the start of the WPC release and for a year after the release were reported by 27 medical institutes in Japan. Transfusion information for approximately 8% of the amount of PCs supplied in Japan was analyzed during the study period. After the start of WPC release by the JRCS, the number of transfused WPCs doubled. The rate of adverse reactions to PCs decreased significantly (p = 0.0223), from 4.30% before the release to 4.05% after the release. The rates of adverse reactions to unwashed and WPCs were 4.13% and 0.84%, respectively. Allergic adverse reactions were significantly decreased after the release (3.60% before versus 3.37% after). No severe allergic reactions to WPCs were reported. The release of WPCs by the JRCS significantly reduced transfusion-related adverse reactions to PCs in Japan. | ||
| 520 | |a Plasma removal by washing platelet concentrates (PCs) is effective in preventing adverse reactions to PC transfusions. The Japanese Red Cross Society (JRCS) started releasing washed PCs (WPCs) as a commercially approved blood product in September 2016. This retrospective multicenter study investigated the change in the number of transfused WPCs and the impact on the incidence of adverse reactions to PCs before and after the release. The numbers and types of transfused PCs and the adverse reactions to the PCs for a year before the start of the WPC release and for a year after the release were reported by 27 medical institutes in Japan. Transfusion information for approximately 8% of the amount of PCs supplied in Japan was analyzed during the study period. After the start of WPC release by the JRCS, the number of transfused WPCs doubled. The rate of adverse reactions to PCs decreased significantly (p = 0.0223), from 4.30% before the release to 4.05% after the release. The rates of adverse reactions to unwashed and WPCs were 4.13% and 0.84%, respectively. Allergic adverse reactions were significantly decreased after the release (3.60% before versus 3.37% after). No severe allergic reactions to WPCs were reported. The release of WPCs by the JRCS significantly reduced transfusion-related adverse reactions to PCs in Japan. | ||
| 650 | 7 | |a Allergic transfusion reaction |2 Elsevier | |
| 650 | 7 | |a Hemovigilance |2 Elsevier | |
| 650 | 7 | |a Replaced platelet concentrate |2 Elsevier | |
| 650 | 7 | |a Adverse transfusion reaction |2 Elsevier | |
| 650 | 7 | |a Washed platelet concentrate |2 Elsevier | |
| 700 | 1 | |a Matsuoka, Sahoko |4 oth | |
| 700 | 1 | |a Tanaka, Asashi |4 oth | |
| 700 | 1 | |a Yonemura, Yuji |4 oth | |
| 700 | 1 | |a Fujii, Yasuhiko |4 oth | |
| 700 | 1 | |a Ohsaka, Akimichi |4 oth | |
| 700 | 1 | |a Okazaki, Hitoshi |4 oth | |
| 700 | 1 | |a Kitazawa, Junichi |4 oth | |
| 700 | 1 | |a Ohtani, Shinichi |4 oth | |
| 700 | 1 | |a Nakayama, Takayuki |4 oth | |
| 700 | 1 | |a Momose, Shun-ya |4 oth | |
| 700 | 1 | |a Miwa, Izumi |4 oth | |
| 700 | 1 | |a Taira, Rikizo |4 oth | |
| 700 | 1 | |a Toyota, Kuro |4 oth | |
| 700 | 1 | |a Kino, Shuichi |4 oth | |
| 700 | 1 | |a Kato, Hidefumi |4 oth | |
| 700 | 1 | |a Hamaguchi, Isao |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier [u.a.] |a Lopategi, A. ELSEVIER |t Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease |d 2016 |d official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis |g Oxford |w (DE-627)ELV01380703X |
| 773 | 1 | 8 | |g volume:58 |g year:2019 |g number:2 |g pages:162-168 |g extent:7 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.transci.2018.12.021 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_26 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_252 | ||
| 936 | b | k | |a 44.44 |j Parasitologie |x Medizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 58 |j 2019 |e 2 |h 162-168 |g 7 | ||
| author_variant |
e i ei |
|---|---|
| matchkey_str |
ikebeemimatsuokasahokotanakaasashiyonemu:2019----:eutoiavrernfsoratosihnraeuefahdltltocnrtsna |
| hierarchy_sort_str |
2019transfer abstract |
| bklnumber |
44.44 |
| publishDate |
2019 |
| allfields |
10.1016/j.transci.2018.12.021 doi GBV00000000000598.pica (DE-627)ELV046545433 (ELSEVIER)S1473-0502(18)30416-6 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.44 bkl Ikebe, Emi verfasserin aut Reduction in adverse transfusion reactions with increased use of washed platelet concentrates in Japan—A retrospective multicenter study 2019transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Plasma removal by washing platelet concentrates (PCs) is effective in preventing adverse reactions to PC transfusions. The Japanese Red Cross Society (JRCS) started releasing washed PCs (WPCs) as a commercially approved blood product in September 2016. This retrospective multicenter study investigated the change in the number of transfused WPCs and the impact on the incidence of adverse reactions to PCs before and after the release. The numbers and types of transfused PCs and the adverse reactions to the PCs for a year before the start of the WPC release and for a year after the release were reported by 27 medical institutes in Japan. Transfusion information for approximately 8% of the amount of PCs supplied in Japan was analyzed during the study period. After the start of WPC release by the JRCS, the number of transfused WPCs doubled. The rate of adverse reactions to PCs decreased significantly (p = 0.0223), from 4.30% before the release to 4.05% after the release. The rates of adverse reactions to unwashed and WPCs were 4.13% and 0.84%, respectively. Allergic adverse reactions were significantly decreased after the release (3.60% before versus 3.37% after). No severe allergic reactions to WPCs were reported. The release of WPCs by the JRCS significantly reduced transfusion-related adverse reactions to PCs in Japan. Plasma removal by washing platelet concentrates (PCs) is effective in preventing adverse reactions to PC transfusions. The Japanese Red Cross Society (JRCS) started releasing washed PCs (WPCs) as a commercially approved blood product in September 2016. This retrospective multicenter study investigated the change in the number of transfused WPCs and the impact on the incidence of adverse reactions to PCs before and after the release. The numbers and types of transfused PCs and the adverse reactions to the PCs for a year before the start of the WPC release and for a year after the release were reported by 27 medical institutes in Japan. Transfusion information for approximately 8% of the amount of PCs supplied in Japan was analyzed during the study period. After the start of WPC release by the JRCS, the number of transfused WPCs doubled. The rate of adverse reactions to PCs decreased significantly (p = 0.0223), from 4.30% before the release to 4.05% after the release. The rates of adverse reactions to unwashed and WPCs were 4.13% and 0.84%, respectively. Allergic adverse reactions were significantly decreased after the release (3.60% before versus 3.37% after). No severe allergic reactions to WPCs were reported. The release of WPCs by the JRCS significantly reduced transfusion-related adverse reactions to PCs in Japan. Allergic transfusion reaction Elsevier Hemovigilance Elsevier Replaced platelet concentrate Elsevier Adverse transfusion reaction Elsevier Washed platelet concentrate Elsevier Matsuoka, Sahoko oth Tanaka, Asashi oth Yonemura, Yuji oth Fujii, Yasuhiko oth Ohsaka, Akimichi oth Okazaki, Hitoshi oth Kitazawa, Junichi oth Ohtani, Shinichi oth Nakayama, Takayuki oth Momose, Shun-ya oth Miwa, Izumi oth Taira, Rikizo oth Toyota, Kuro oth Kino, Shuichi oth Kato, Hidefumi oth Hamaguchi, Isao oth Enthalten in Elsevier [u.a.] Lopategi, A. ELSEVIER Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease 2016 official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis Oxford (DE-627)ELV01380703X volume:58 year:2019 number:2 pages:162-168 extent:7 https://doi.org/10.1016/j.transci.2018.12.021 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_26 GBV_ILN_40 GBV_ILN_252 44.44 Parasitologie Medizin VZ AR 58 2019 2 162-168 7 |
| spelling |
10.1016/j.transci.2018.12.021 doi GBV00000000000598.pica (DE-627)ELV046545433 (ELSEVIER)S1473-0502(18)30416-6 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.44 bkl Ikebe, Emi verfasserin aut Reduction in adverse transfusion reactions with increased use of washed platelet concentrates in Japan—A retrospective multicenter study 2019transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Plasma removal by washing platelet concentrates (PCs) is effective in preventing adverse reactions to PC transfusions. The Japanese Red Cross Society (JRCS) started releasing washed PCs (WPCs) as a commercially approved blood product in September 2016. This retrospective multicenter study investigated the change in the number of transfused WPCs and the impact on the incidence of adverse reactions to PCs before and after the release. The numbers and types of transfused PCs and the adverse reactions to the PCs for a year before the start of the WPC release and for a year after the release were reported by 27 medical institutes in Japan. Transfusion information for approximately 8% of the amount of PCs supplied in Japan was analyzed during the study period. After the start of WPC release by the JRCS, the number of transfused WPCs doubled. The rate of adverse reactions to PCs decreased significantly (p = 0.0223), from 4.30% before the release to 4.05% after the release. The rates of adverse reactions to unwashed and WPCs were 4.13% and 0.84%, respectively. Allergic adverse reactions were significantly decreased after the release (3.60% before versus 3.37% after). No severe allergic reactions to WPCs were reported. The release of WPCs by the JRCS significantly reduced transfusion-related adverse reactions to PCs in Japan. Plasma removal by washing platelet concentrates (PCs) is effective in preventing adverse reactions to PC transfusions. The Japanese Red Cross Society (JRCS) started releasing washed PCs (WPCs) as a commercially approved blood product in September 2016. This retrospective multicenter study investigated the change in the number of transfused WPCs and the impact on the incidence of adverse reactions to PCs before and after the release. The numbers and types of transfused PCs and the adverse reactions to the PCs for a year before the start of the WPC release and for a year after the release were reported by 27 medical institutes in Japan. Transfusion information for approximately 8% of the amount of PCs supplied in Japan was analyzed during the study period. After the start of WPC release by the JRCS, the number of transfused WPCs doubled. The rate of adverse reactions to PCs decreased significantly (p = 0.0223), from 4.30% before the release to 4.05% after the release. The rates of adverse reactions to unwashed and WPCs were 4.13% and 0.84%, respectively. Allergic adverse reactions were significantly decreased after the release (3.60% before versus 3.37% after). No severe allergic reactions to WPCs were reported. The release of WPCs by the JRCS significantly reduced transfusion-related adverse reactions to PCs in Japan. Allergic transfusion reaction Elsevier Hemovigilance Elsevier Replaced platelet concentrate Elsevier Adverse transfusion reaction Elsevier Washed platelet concentrate Elsevier Matsuoka, Sahoko oth Tanaka, Asashi oth Yonemura, Yuji oth Fujii, Yasuhiko oth Ohsaka, Akimichi oth Okazaki, Hitoshi oth Kitazawa, Junichi oth Ohtani, Shinichi oth Nakayama, Takayuki oth Momose, Shun-ya oth Miwa, Izumi oth Taira, Rikizo oth Toyota, Kuro oth Kino, Shuichi oth Kato, Hidefumi oth Hamaguchi, Isao oth Enthalten in Elsevier [u.a.] Lopategi, A. ELSEVIER Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease 2016 official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis Oxford (DE-627)ELV01380703X volume:58 year:2019 number:2 pages:162-168 extent:7 https://doi.org/10.1016/j.transci.2018.12.021 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_26 GBV_ILN_40 GBV_ILN_252 44.44 Parasitologie Medizin VZ AR 58 2019 2 162-168 7 |
| allfields_unstemmed |
10.1016/j.transci.2018.12.021 doi GBV00000000000598.pica (DE-627)ELV046545433 (ELSEVIER)S1473-0502(18)30416-6 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.44 bkl Ikebe, Emi verfasserin aut Reduction in adverse transfusion reactions with increased use of washed platelet concentrates in Japan—A retrospective multicenter study 2019transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Plasma removal by washing platelet concentrates (PCs) is effective in preventing adverse reactions to PC transfusions. The Japanese Red Cross Society (JRCS) started releasing washed PCs (WPCs) as a commercially approved blood product in September 2016. This retrospective multicenter study investigated the change in the number of transfused WPCs and the impact on the incidence of adverse reactions to PCs before and after the release. The numbers and types of transfused PCs and the adverse reactions to the PCs for a year before the start of the WPC release and for a year after the release were reported by 27 medical institutes in Japan. Transfusion information for approximately 8% of the amount of PCs supplied in Japan was analyzed during the study period. After the start of WPC release by the JRCS, the number of transfused WPCs doubled. The rate of adverse reactions to PCs decreased significantly (p = 0.0223), from 4.30% before the release to 4.05% after the release. The rates of adverse reactions to unwashed and WPCs were 4.13% and 0.84%, respectively. Allergic adverse reactions were significantly decreased after the release (3.60% before versus 3.37% after). No severe allergic reactions to WPCs were reported. The release of WPCs by the JRCS significantly reduced transfusion-related adverse reactions to PCs in Japan. Plasma removal by washing platelet concentrates (PCs) is effective in preventing adverse reactions to PC transfusions. The Japanese Red Cross Society (JRCS) started releasing washed PCs (WPCs) as a commercially approved blood product in September 2016. This retrospective multicenter study investigated the change in the number of transfused WPCs and the impact on the incidence of adverse reactions to PCs before and after the release. The numbers and types of transfused PCs and the adverse reactions to the PCs for a year before the start of the WPC release and for a year after the release were reported by 27 medical institutes in Japan. Transfusion information for approximately 8% of the amount of PCs supplied in Japan was analyzed during the study period. After the start of WPC release by the JRCS, the number of transfused WPCs doubled. The rate of adverse reactions to PCs decreased significantly (p = 0.0223), from 4.30% before the release to 4.05% after the release. The rates of adverse reactions to unwashed and WPCs were 4.13% and 0.84%, respectively. Allergic adverse reactions were significantly decreased after the release (3.60% before versus 3.37% after). No severe allergic reactions to WPCs were reported. The release of WPCs by the JRCS significantly reduced transfusion-related adverse reactions to PCs in Japan. Allergic transfusion reaction Elsevier Hemovigilance Elsevier Replaced platelet concentrate Elsevier Adverse transfusion reaction Elsevier Washed platelet concentrate Elsevier Matsuoka, Sahoko oth Tanaka, Asashi oth Yonemura, Yuji oth Fujii, Yasuhiko oth Ohsaka, Akimichi oth Okazaki, Hitoshi oth Kitazawa, Junichi oth Ohtani, Shinichi oth Nakayama, Takayuki oth Momose, Shun-ya oth Miwa, Izumi oth Taira, Rikizo oth Toyota, Kuro oth Kino, Shuichi oth Kato, Hidefumi oth Hamaguchi, Isao oth Enthalten in Elsevier [u.a.] Lopategi, A. ELSEVIER Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease 2016 official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis Oxford (DE-627)ELV01380703X volume:58 year:2019 number:2 pages:162-168 extent:7 https://doi.org/10.1016/j.transci.2018.12.021 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_26 GBV_ILN_40 GBV_ILN_252 44.44 Parasitologie Medizin VZ AR 58 2019 2 162-168 7 |
| allfieldsGer |
10.1016/j.transci.2018.12.021 doi GBV00000000000598.pica (DE-627)ELV046545433 (ELSEVIER)S1473-0502(18)30416-6 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.44 bkl Ikebe, Emi verfasserin aut Reduction in adverse transfusion reactions with increased use of washed platelet concentrates in Japan—A retrospective multicenter study 2019transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Plasma removal by washing platelet concentrates (PCs) is effective in preventing adverse reactions to PC transfusions. The Japanese Red Cross Society (JRCS) started releasing washed PCs (WPCs) as a commercially approved blood product in September 2016. This retrospective multicenter study investigated the change in the number of transfused WPCs and the impact on the incidence of adverse reactions to PCs before and after the release. The numbers and types of transfused PCs and the adverse reactions to the PCs for a year before the start of the WPC release and for a year after the release were reported by 27 medical institutes in Japan. Transfusion information for approximately 8% of the amount of PCs supplied in Japan was analyzed during the study period. After the start of WPC release by the JRCS, the number of transfused WPCs doubled. The rate of adverse reactions to PCs decreased significantly (p = 0.0223), from 4.30% before the release to 4.05% after the release. The rates of adverse reactions to unwashed and WPCs were 4.13% and 0.84%, respectively. Allergic adverse reactions were significantly decreased after the release (3.60% before versus 3.37% after). No severe allergic reactions to WPCs were reported. The release of WPCs by the JRCS significantly reduced transfusion-related adverse reactions to PCs in Japan. Plasma removal by washing platelet concentrates (PCs) is effective in preventing adverse reactions to PC transfusions. The Japanese Red Cross Society (JRCS) started releasing washed PCs (WPCs) as a commercially approved blood product in September 2016. This retrospective multicenter study investigated the change in the number of transfused WPCs and the impact on the incidence of adverse reactions to PCs before and after the release. The numbers and types of transfused PCs and the adverse reactions to the PCs for a year before the start of the WPC release and for a year after the release were reported by 27 medical institutes in Japan. Transfusion information for approximately 8% of the amount of PCs supplied in Japan was analyzed during the study period. After the start of WPC release by the JRCS, the number of transfused WPCs doubled. The rate of adverse reactions to PCs decreased significantly (p = 0.0223), from 4.30% before the release to 4.05% after the release. The rates of adverse reactions to unwashed and WPCs were 4.13% and 0.84%, respectively. Allergic adverse reactions were significantly decreased after the release (3.60% before versus 3.37% after). No severe allergic reactions to WPCs were reported. The release of WPCs by the JRCS significantly reduced transfusion-related adverse reactions to PCs in Japan. Allergic transfusion reaction Elsevier Hemovigilance Elsevier Replaced platelet concentrate Elsevier Adverse transfusion reaction Elsevier Washed platelet concentrate Elsevier Matsuoka, Sahoko oth Tanaka, Asashi oth Yonemura, Yuji oth Fujii, Yasuhiko oth Ohsaka, Akimichi oth Okazaki, Hitoshi oth Kitazawa, Junichi oth Ohtani, Shinichi oth Nakayama, Takayuki oth Momose, Shun-ya oth Miwa, Izumi oth Taira, Rikizo oth Toyota, Kuro oth Kino, Shuichi oth Kato, Hidefumi oth Hamaguchi, Isao oth Enthalten in Elsevier [u.a.] Lopategi, A. ELSEVIER Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease 2016 official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis Oxford (DE-627)ELV01380703X volume:58 year:2019 number:2 pages:162-168 extent:7 https://doi.org/10.1016/j.transci.2018.12.021 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_26 GBV_ILN_40 GBV_ILN_252 44.44 Parasitologie Medizin VZ AR 58 2019 2 162-168 7 |
| allfieldsSound |
10.1016/j.transci.2018.12.021 doi GBV00000000000598.pica (DE-627)ELV046545433 (ELSEVIER)S1473-0502(18)30416-6 DE-627 ger DE-627 rakwb eng 610 VZ 610 VZ 44.44 bkl Ikebe, Emi verfasserin aut Reduction in adverse transfusion reactions with increased use of washed platelet concentrates in Japan—A retrospective multicenter study 2019transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Plasma removal by washing platelet concentrates (PCs) is effective in preventing adverse reactions to PC transfusions. The Japanese Red Cross Society (JRCS) started releasing washed PCs (WPCs) as a commercially approved blood product in September 2016. This retrospective multicenter study investigated the change in the number of transfused WPCs and the impact on the incidence of adverse reactions to PCs before and after the release. The numbers and types of transfused PCs and the adverse reactions to the PCs for a year before the start of the WPC release and for a year after the release were reported by 27 medical institutes in Japan. Transfusion information for approximately 8% of the amount of PCs supplied in Japan was analyzed during the study period. After the start of WPC release by the JRCS, the number of transfused WPCs doubled. The rate of adverse reactions to PCs decreased significantly (p = 0.0223), from 4.30% before the release to 4.05% after the release. The rates of adverse reactions to unwashed and WPCs were 4.13% and 0.84%, respectively. Allergic adverse reactions were significantly decreased after the release (3.60% before versus 3.37% after). No severe allergic reactions to WPCs were reported. The release of WPCs by the JRCS significantly reduced transfusion-related adverse reactions to PCs in Japan. Plasma removal by washing platelet concentrates (PCs) is effective in preventing adverse reactions to PC transfusions. The Japanese Red Cross Society (JRCS) started releasing washed PCs (WPCs) as a commercially approved blood product in September 2016. This retrospective multicenter study investigated the change in the number of transfused WPCs and the impact on the incidence of adverse reactions to PCs before and after the release. The numbers and types of transfused PCs and the adverse reactions to the PCs for a year before the start of the WPC release and for a year after the release were reported by 27 medical institutes in Japan. Transfusion information for approximately 8% of the amount of PCs supplied in Japan was analyzed during the study period. After the start of WPC release by the JRCS, the number of transfused WPCs doubled. The rate of adverse reactions to PCs decreased significantly (p = 0.0223), from 4.30% before the release to 4.05% after the release. The rates of adverse reactions to unwashed and WPCs were 4.13% and 0.84%, respectively. Allergic adverse reactions were significantly decreased after the release (3.60% before versus 3.37% after). No severe allergic reactions to WPCs were reported. The release of WPCs by the JRCS significantly reduced transfusion-related adverse reactions to PCs in Japan. Allergic transfusion reaction Elsevier Hemovigilance Elsevier Replaced platelet concentrate Elsevier Adverse transfusion reaction Elsevier Washed platelet concentrate Elsevier Matsuoka, Sahoko oth Tanaka, Asashi oth Yonemura, Yuji oth Fujii, Yasuhiko oth Ohsaka, Akimichi oth Okazaki, Hitoshi oth Kitazawa, Junichi oth Ohtani, Shinichi oth Nakayama, Takayuki oth Momose, Shun-ya oth Miwa, Izumi oth Taira, Rikizo oth Toyota, Kuro oth Kino, Shuichi oth Kato, Hidefumi oth Hamaguchi, Isao oth Enthalten in Elsevier [u.a.] Lopategi, A. ELSEVIER Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease 2016 official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis Oxford (DE-627)ELV01380703X volume:58 year:2019 number:2 pages:162-168 extent:7 https://doi.org/10.1016/j.transci.2018.12.021 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_26 GBV_ILN_40 GBV_ILN_252 44.44 Parasitologie Medizin VZ AR 58 2019 2 162-168 7 |
| language |
English |
| source |
Enthalten in Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease Oxford volume:58 year:2019 number:2 pages:162-168 extent:7 |
| sourceStr |
Enthalten in Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease Oxford volume:58 year:2019 number:2 pages:162-168 extent:7 |
| format_phy_str_mv |
Article |
| bklname |
Parasitologie |
| institution |
findex.gbv.de |
| topic_facet |
Allergic transfusion reaction Hemovigilance Replaced platelet concentrate Adverse transfusion reaction Washed platelet concentrate |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease |
| authorswithroles_txt_mv |
Ikebe, Emi @@aut@@ Matsuoka, Sahoko @@oth@@ Tanaka, Asashi @@oth@@ Yonemura, Yuji @@oth@@ Fujii, Yasuhiko @@oth@@ Ohsaka, Akimichi @@oth@@ Okazaki, Hitoshi @@oth@@ Kitazawa, Junichi @@oth@@ Ohtani, Shinichi @@oth@@ Nakayama, Takayuki @@oth@@ Momose, Shun-ya @@oth@@ Miwa, Izumi @@oth@@ Taira, Rikizo @@oth@@ Toyota, Kuro @@oth@@ Kino, Shuichi @@oth@@ Kato, Hidefumi @@oth@@ Hamaguchi, Isao @@oth@@ |
| publishDateDaySort_date |
2019-01-01T00:00:00Z |
| hierarchy_top_id |
ELV01380703X |
| dewey-sort |
3610 |
| id |
ELV046545433 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV046545433</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626013912.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">191021s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.transci.2018.12.021</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000598.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV046545433</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1473-0502(18)30416-6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.44</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ikebe, Emi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Reduction in adverse transfusion reactions with increased use of washed platelet concentrates in Japan—A retrospective multicenter study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Plasma removal by washing platelet concentrates (PCs) is effective in preventing adverse reactions to PC transfusions. The Japanese Red Cross Society (JRCS) started releasing washed PCs (WPCs) as a commercially approved blood product in September 2016. This retrospective multicenter study investigated the change in the number of transfused WPCs and the impact on the incidence of adverse reactions to PCs before and after the release. The numbers and types of transfused PCs and the adverse reactions to the PCs for a year before the start of the WPC release and for a year after the release were reported by 27 medical institutes in Japan. Transfusion information for approximately 8% of the amount of PCs supplied in Japan was analyzed during the study period. After the start of WPC release by the JRCS, the number of transfused WPCs doubled. The rate of adverse reactions to PCs decreased significantly (p = 0.0223), from 4.30% before the release to 4.05% after the release. The rates of adverse reactions to unwashed and WPCs were 4.13% and 0.84%, respectively. Allergic adverse reactions were significantly decreased after the release (3.60% before versus 3.37% after). No severe allergic reactions to WPCs were reported. The release of WPCs by the JRCS significantly reduced transfusion-related adverse reactions to PCs in Japan.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Plasma removal by washing platelet concentrates (PCs) is effective in preventing adverse reactions to PC transfusions. The Japanese Red Cross Society (JRCS) started releasing washed PCs (WPCs) as a commercially approved blood product in September 2016. This retrospective multicenter study investigated the change in the number of transfused WPCs and the impact on the incidence of adverse reactions to PCs before and after the release. The numbers and types of transfused PCs and the adverse reactions to the PCs for a year before the start of the WPC release and for a year after the release were reported by 27 medical institutes in Japan. Transfusion information for approximately 8% of the amount of PCs supplied in Japan was analyzed during the study period. After the start of WPC release by the JRCS, the number of transfused WPCs doubled. The rate of adverse reactions to PCs decreased significantly (p = 0.0223), from 4.30% before the release to 4.05% after the release. The rates of adverse reactions to unwashed and WPCs were 4.13% and 0.84%, respectively. Allergic adverse reactions were significantly decreased after the release (3.60% before versus 3.37% after). No severe allergic reactions to WPCs were reported. The release of WPCs by the JRCS significantly reduced transfusion-related adverse reactions to PCs in Japan.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Allergic transfusion reaction</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Hemovigilance</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Replaced platelet concentrate</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Adverse transfusion reaction</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Washed platelet concentrate</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Matsuoka, Sahoko</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tanaka, Asashi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yonemura, Yuji</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fujii, Yasuhiko</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ohsaka, Akimichi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Okazaki, Hitoshi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kitazawa, Junichi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ohtani, Shinichi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nakayama, Takayuki</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Momose, Shun-ya</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Miwa, Izumi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Taira, Rikizo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Toyota, Kuro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kino, Shuichi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kato, Hidefumi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hamaguchi, Isao</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier [u.a.]</subfield><subfield code="a">Lopategi, A. ELSEVIER</subfield><subfield code="t">Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease</subfield><subfield code="d">2016</subfield><subfield code="d">official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis</subfield><subfield code="g">Oxford</subfield><subfield code="w">(DE-627)ELV01380703X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:58</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:162-168</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.transci.2018.12.021</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_26</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_252</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.44</subfield><subfield code="j">Parasitologie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">58</subfield><subfield code="j">2019</subfield><subfield code="e">2</subfield><subfield code="h">162-168</subfield><subfield code="g">7</subfield></datafield></record></collection>
|
| author |
Ikebe, Emi |
| spellingShingle |
Ikebe, Emi ddc 610 bkl 44.44 Elsevier Allergic transfusion reaction Elsevier Hemovigilance Elsevier Replaced platelet concentrate Elsevier Adverse transfusion reaction Elsevier Washed platelet concentrate Reduction in adverse transfusion reactions with increased use of washed platelet concentrates in Japan—A retrospective multicenter study |
| authorStr |
Ikebe, Emi |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV01380703X |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 44.44 bkl Reduction in adverse transfusion reactions with increased use of washed platelet concentrates in Japan—A retrospective multicenter study Allergic transfusion reaction Elsevier Hemovigilance Elsevier Replaced platelet concentrate Elsevier Adverse transfusion reaction Elsevier Washed platelet concentrate Elsevier |
| topic |
ddc 610 bkl 44.44 Elsevier Allergic transfusion reaction Elsevier Hemovigilance Elsevier Replaced platelet concentrate Elsevier Adverse transfusion reaction Elsevier Washed platelet concentrate |
| topic_unstemmed |
ddc 610 bkl 44.44 Elsevier Allergic transfusion reaction Elsevier Hemovigilance Elsevier Replaced platelet concentrate Elsevier Adverse transfusion reaction Elsevier Washed platelet concentrate |
| topic_browse |
ddc 610 bkl 44.44 Elsevier Allergic transfusion reaction Elsevier Hemovigilance Elsevier Replaced platelet concentrate Elsevier Adverse transfusion reaction Elsevier Washed platelet concentrate |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
s m sm a t at y y yy y f yf a o ao h o ho j k jk s o so t n tn s y m sym i m im r t rt k t kt s k sk h k hk i h ih |
| hierarchy_parent_title |
Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease |
| hierarchy_parent_id |
ELV01380703X |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV01380703X |
| title |
Reduction in adverse transfusion reactions with increased use of washed platelet concentrates in Japan—A retrospective multicenter study |
| ctrlnum |
(DE-627)ELV046545433 (ELSEVIER)S1473-0502(18)30416-6 |
| title_full |
Reduction in adverse transfusion reactions with increased use of washed platelet concentrates in Japan—A retrospective multicenter study |
| author_sort |
Ikebe, Emi |
| journal |
Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease |
| journalStr |
Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2019 |
| contenttype_str_mv |
zzz |
| container_start_page |
162 |
| author_browse |
Ikebe, Emi |
| container_volume |
58 |
| physical |
7 |
| class |
610 VZ 44.44 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Ikebe, Emi |
| doi_str_mv |
10.1016/j.transci.2018.12.021 |
| dewey-full |
610 |
| title_sort |
reduction in adverse transfusion reactions with increased use of washed platelet concentrates in japan—a retrospective multicenter study |
| title_auth |
Reduction in adverse transfusion reactions with increased use of washed platelet concentrates in Japan—A retrospective multicenter study |
| abstract |
Plasma removal by washing platelet concentrates (PCs) is effective in preventing adverse reactions to PC transfusions. The Japanese Red Cross Society (JRCS) started releasing washed PCs (WPCs) as a commercially approved blood product in September 2016. This retrospective multicenter study investigated the change in the number of transfused WPCs and the impact on the incidence of adverse reactions to PCs before and after the release. The numbers and types of transfused PCs and the adverse reactions to the PCs for a year before the start of the WPC release and for a year after the release were reported by 27 medical institutes in Japan. Transfusion information for approximately 8% of the amount of PCs supplied in Japan was analyzed during the study period. After the start of WPC release by the JRCS, the number of transfused WPCs doubled. The rate of adverse reactions to PCs decreased significantly (p = 0.0223), from 4.30% before the release to 4.05% after the release. The rates of adverse reactions to unwashed and WPCs were 4.13% and 0.84%, respectively. Allergic adverse reactions were significantly decreased after the release (3.60% before versus 3.37% after). No severe allergic reactions to WPCs were reported. The release of WPCs by the JRCS significantly reduced transfusion-related adverse reactions to PCs in Japan. |
| abstractGer |
Plasma removal by washing platelet concentrates (PCs) is effective in preventing adverse reactions to PC transfusions. The Japanese Red Cross Society (JRCS) started releasing washed PCs (WPCs) as a commercially approved blood product in September 2016. This retrospective multicenter study investigated the change in the number of transfused WPCs and the impact on the incidence of adverse reactions to PCs before and after the release. The numbers and types of transfused PCs and the adverse reactions to the PCs for a year before the start of the WPC release and for a year after the release were reported by 27 medical institutes in Japan. Transfusion information for approximately 8% of the amount of PCs supplied in Japan was analyzed during the study period. After the start of WPC release by the JRCS, the number of transfused WPCs doubled. The rate of adverse reactions to PCs decreased significantly (p = 0.0223), from 4.30% before the release to 4.05% after the release. The rates of adverse reactions to unwashed and WPCs were 4.13% and 0.84%, respectively. Allergic adverse reactions were significantly decreased after the release (3.60% before versus 3.37% after). No severe allergic reactions to WPCs were reported. The release of WPCs by the JRCS significantly reduced transfusion-related adverse reactions to PCs in Japan. |
| abstract_unstemmed |
Plasma removal by washing platelet concentrates (PCs) is effective in preventing adverse reactions to PC transfusions. The Japanese Red Cross Society (JRCS) started releasing washed PCs (WPCs) as a commercially approved blood product in September 2016. This retrospective multicenter study investigated the change in the number of transfused WPCs and the impact on the incidence of adverse reactions to PCs before and after the release. The numbers and types of transfused PCs and the adverse reactions to the PCs for a year before the start of the WPC release and for a year after the release were reported by 27 medical institutes in Japan. Transfusion information for approximately 8% of the amount of PCs supplied in Japan was analyzed during the study period. After the start of WPC release by the JRCS, the number of transfused WPCs doubled. The rate of adverse reactions to PCs decreased significantly (p = 0.0223), from 4.30% before the release to 4.05% after the release. The rates of adverse reactions to unwashed and WPCs were 4.13% and 0.84%, respectively. Allergic adverse reactions were significantly decreased after the release (3.60% before versus 3.37% after). No severe allergic reactions to WPCs were reported. The release of WPCs by the JRCS significantly reduced transfusion-related adverse reactions to PCs in Japan. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_26 GBV_ILN_40 GBV_ILN_252 |
| container_issue |
2 |
| title_short |
Reduction in adverse transfusion reactions with increased use of washed platelet concentrates in Japan—A retrospective multicenter study |
| url |
https://doi.org/10.1016/j.transci.2018.12.021 |
| remote_bool |
true |
| author2 |
Matsuoka, Sahoko Tanaka, Asashi Yonemura, Yuji Fujii, Yasuhiko Ohsaka, Akimichi Okazaki, Hitoshi Kitazawa, Junichi Ohtani, Shinichi Nakayama, Takayuki Momose, Shun-ya Miwa, Izumi Taira, Rikizo Toyota, Kuro Kino, Shuichi Kato, Hidefumi Hamaguchi, Isao |
| author2Str |
Matsuoka, Sahoko Tanaka, Asashi Yonemura, Yuji Fujii, Yasuhiko Ohsaka, Akimichi Okazaki, Hitoshi Kitazawa, Junichi Ohtani, Shinichi Nakayama, Takayuki Momose, Shun-ya Miwa, Izumi Taira, Rikizo Toyota, Kuro Kino, Shuichi Kato, Hidefumi Hamaguchi, Isao |
| ppnlink |
ELV01380703X |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.transci.2018.12.021 |
| up_date |
2024-07-06T20:30:46.584Z |
| _version_ |
1803863034781761536 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV046545433</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626013912.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">191021s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.transci.2018.12.021</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000598.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV046545433</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1473-0502(18)30416-6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.44</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ikebe, Emi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Reduction in adverse transfusion reactions with increased use of washed platelet concentrates in Japan—A retrospective multicenter study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Plasma removal by washing platelet concentrates (PCs) is effective in preventing adverse reactions to PC transfusions. The Japanese Red Cross Society (JRCS) started releasing washed PCs (WPCs) as a commercially approved blood product in September 2016. This retrospective multicenter study investigated the change in the number of transfused WPCs and the impact on the incidence of adverse reactions to PCs before and after the release. The numbers and types of transfused PCs and the adverse reactions to the PCs for a year before the start of the WPC release and for a year after the release were reported by 27 medical institutes in Japan. Transfusion information for approximately 8% of the amount of PCs supplied in Japan was analyzed during the study period. After the start of WPC release by the JRCS, the number of transfused WPCs doubled. The rate of adverse reactions to PCs decreased significantly (p = 0.0223), from 4.30% before the release to 4.05% after the release. The rates of adverse reactions to unwashed and WPCs were 4.13% and 0.84%, respectively. Allergic adverse reactions were significantly decreased after the release (3.60% before versus 3.37% after). No severe allergic reactions to WPCs were reported. The release of WPCs by the JRCS significantly reduced transfusion-related adverse reactions to PCs in Japan.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Plasma removal by washing platelet concentrates (PCs) is effective in preventing adverse reactions to PC transfusions. The Japanese Red Cross Society (JRCS) started releasing washed PCs (WPCs) as a commercially approved blood product in September 2016. This retrospective multicenter study investigated the change in the number of transfused WPCs and the impact on the incidence of adverse reactions to PCs before and after the release. The numbers and types of transfused PCs and the adverse reactions to the PCs for a year before the start of the WPC release and for a year after the release were reported by 27 medical institutes in Japan. Transfusion information for approximately 8% of the amount of PCs supplied in Japan was analyzed during the study period. After the start of WPC release by the JRCS, the number of transfused WPCs doubled. The rate of adverse reactions to PCs decreased significantly (p = 0.0223), from 4.30% before the release to 4.05% after the release. The rates of adverse reactions to unwashed and WPCs were 4.13% and 0.84%, respectively. Allergic adverse reactions were significantly decreased after the release (3.60% before versus 3.37% after). No severe allergic reactions to WPCs were reported. The release of WPCs by the JRCS significantly reduced transfusion-related adverse reactions to PCs in Japan.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Allergic transfusion reaction</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Hemovigilance</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Replaced platelet concentrate</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Adverse transfusion reaction</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Washed platelet concentrate</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Matsuoka, Sahoko</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tanaka, Asashi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yonemura, Yuji</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fujii, Yasuhiko</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ohsaka, Akimichi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Okazaki, Hitoshi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kitazawa, Junichi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ohtani, Shinichi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nakayama, Takayuki</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Momose, Shun-ya</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Miwa, Izumi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Taira, Rikizo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Toyota, Kuro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kino, Shuichi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kato, Hidefumi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hamaguchi, Isao</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier [u.a.]</subfield><subfield code="a">Lopategi, A. ELSEVIER</subfield><subfield code="t">Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease</subfield><subfield code="d">2016</subfield><subfield code="d">official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis</subfield><subfield code="g">Oxford</subfield><subfield code="w">(DE-627)ELV01380703X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:58</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:162-168</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.transci.2018.12.021</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_26</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_252</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.44</subfield><subfield code="j">Parasitologie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">58</subfield><subfield code="j">2019</subfield><subfield code="e">2</subfield><subfield code="h">162-168</subfield><subfield code="g">7</subfield></datafield></record></collection>
|
| score |
7.4006386 |